Kyttaro Therapeutics is one of the few companies with a patent estate across a portfolio of genetically-modified mesenchymal stem cells (MSCs), offering a powerful tool to enhance the viability, homing, and therapeutic function in naïve MSCs.
These genetically-modified MSCs provide more effective and targeted, off the shelf, allogeneic, cell-based therapies in large markets with unmet need, and longevity.
Accomplishments to Date
Kyttaro Therapeutics is headquartered in Philadelphia PA, with scientific roots in Munich, Germany.
The Company was founded to unlock the full therapeutic potential of MSCs through genetic engineering. Kyttaro’s platform generates three proprietary, patent-protected, genetically modified MSC cell lines — MSC-AAT, MSC-Cytokine (MSC-Cyt), and MSC-Klotho — each of which addresses significant unmet medical needs across multiple large-market indications. The Company has also developed patents on naïve MSCs with CAR-T cells designed to enhance the anti-tumor activity of immunotherapy.
Kyttaro’s intellectual property and preclinical data were originally generated over more than a decade at Apceth Biopharma GmbH (Munich), representing over $40 million in R&D investment. That work established the genetic modification protocols, bioreactor manufacturing processes, and initial clinical evidence that form the foundation of Kyttaro’s programs today. This data is available under NDA to qualified investors and partners.
We have developed a robust patent portfolio across three varieties of genetically-modified MSC's.
Swipe sideways to view the full patent portfolio →
Kyttaro wholly owns the entire patent estate created by Apceth Biopharma GmbH. The IP was assigned to Kyttaro by contract from JuntuCell (which had received it when Apceth's manufacturing business was sold to Hitachi Chemical/Minaris in 2019). Certain patent registers may still list a prior holder pending administrative re-recording of assignments; however, beneficial and legal ownership rests with Kyttaro Therapeutics, Inc.
All Apceth scientific and operational documentation has been assembled into a Kyttaro Document Database comprising 8 years of patented R&D and pre-clinical work that is now readily accessible via a retrieval augmented generative AI system named Kyttaro Document Intelligence.
Leadership
Kyttaro is led by an internationally recognized executive team and scientific / strategic advisory boards with deep industry knowledge and experience.The founding team combines deep expertise in cell and gene therapy, clinical development, regulatory strategy, healthcare investment, and corporate law. Our Scientific Advisory Board includes leading physicians from Children’s Hospital of Philadelphia, Johns Hopkins University, and Albert Einstein College of Medicine / Montefiore.
Operations
Kyttaro’s operations are headquartered at BioLabs Philadelphia (co-working and shared lab space with ancillary operations in Munich), and will collaborate with Thermo Fisher’s Advanced Therapies Collaboration Center there to create comprehensive, end- to-end manufacturing workflows.
Infrastructure
Kyttaro has formed a Supply Agreement with the New York Blood Center and has access to its FDA approved Master Cell Bank of umbilical cord-derived mesenchymal stem cells already being used for cell transplantation procedures with appropriate preparative regimens.
Pipeline
The Company has chosen MSC-Klotho for neurodegenerative disease and longevity as its initial product candidate and has established a partnership to perform in-vivo, proof of concept studies for ALS within nine months of commencement.
MSC-AAT was approved by the German authorities and prepared to initiate a Phase I/II clinical study in steroid-refractory GvHD in Europe, demonstrating long-term survival in over 50% of the research subjects and anti-inflammatory activity compared to naïve MSCs. Kyttaro is now prepared to commence discussions with the FDA in the US. The FDA recently approved Mesoblast’s Ryoncil for the pediatric population in GvHD, the first MSC therapy ever approved in the US, which validates the modality.
MSC-Klotho is a patent protected ALS program designed to reach its next major value inflection over 24 months.
0-6 months
Preclinical Workup
Randomized design, route / regimen, comparator arms
6-12 months
Blinded efficacy readout
Survival, motor function, biomarkers
12-18 months
Second ALS model
Translatability + direct add-on value
18-24 months
Translation package
Potency, release, biodistribution, FDA-ready path
24 months
Results
- Direct efficacy
- Biomarkers
- Series A package